CROI 2023 Tuberculosis Research Round Up
Treatment Action Group (TAG) welcomes the tuberculosis (TB) data presented at the 2023 Conference on Retroviruses and Opportunistic Infections (CROI).
TB Treatment Trial Results in Context for Communities
On Tuesday, March 14 at 8:00 am ET, join Treatment Action Group (TAG) and Dr. Jennifer Furin for an overview of key results and breakdown of how they fit into the larger TB policy and research landscapes.
2023 Pre-CROI Community HIV Cure Research Workshop
The 2023 Pre-CROI Community HIV Cure Research Workshop will be held on Saturday, February 18th in the Sequoia Glacier Room at Crowne Plaza Hotel, 1113 - 6th Avenue, Seattle, WA 98101.
Advocating for the Integration of Viral Hepatitis Prevention and Treatment for People Who Use Drugs in PEPFAR COPs
On January 24, 2022, Treatment Action Group (TAG), World Hepatitis Alliance (WHA), Harm Reduction International (HRI), the International Network of People Who Use Drugs (INPUD), and the International Drug Policy Consortium (IDPC) will host a webinar, “Advocating for the Integration of Viral Hepatitis Prevention and Treatment for People Who Use Drugs in PEFPFAR COPs."
Risk of Breakthrough COVID-19 Infections and Disease in Vaccinated People with HIV
This fact sheet on breakthrough COVID-19 infections among people living with HIV was co-produced by TAG and our partners the Black AIDS Institute, Southern AIDS Coalition and the COVID-19 Prevention Network.
2022 TAG Update
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.
2022 Report on TB Research Funding Trends
For the first time in history, funding for tuberculosis (TB) research and development (R&D) hit a billion dollars worldwide in 2021.
Response to Tuberculosis Treatment Trials Results Published and Presented During the 2022 Union World Conference on Lung Health
Treatment Action Group (TAG) and the Global Tuberculosis Community Advisory Board (TB CAB) welcome the clinical trials results recently published and presented during the 2022 Union World Conference on Lung Health, which evaluated shorter regimens and treatment shortening strategies for drug-sensitive and drug-resistant tuberculosis.
1/4/6×24 Community Campaign Training Materials
Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…
Introducing 1/4/6×24: A Campaign That Draws Inspiration from the Past to Change the Trajectory of the Future Fight to End Tuberculosis
By Lindsay McKenna, Mike Frick, and Mark Harrington At the 24th International AIDS Conference in Montreal this summer, TAG, Partners In Health (PIH), and Médecins Sans Frontières (MSF) launched the 1/4/6x24 Campaign to accelerate equitable global uptake of newly discovered…